SVCM
IMMX icon

Saturn V Capital Management’s Immix Biopharma IMMX Stock Holding History

Saturn V Capital Management’s Portfolio IMMX Stock Details IMMX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$33.6M Buy
3,693,585
+694,416
+23% +$5.1M 6.09% 6
2025
Q4 		$15.7M Buy
+2,999,169
New +$12.3M 2.88% 15

Other funds holding IMMX

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return
BL
Bleichroeder LP New York $579M AUM 94.36% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
VCIM
Velan Capital Investment Management Alpharetta, Georgia $160M AUM 517.12% 1-Year Est. Return
BOCH
Blue Owl Capital Holdings New York $372M AUM 78.25% 1-Year Est. Return

Saturn V Capital Management's IMMX Position: Q1 2026 in Review

Saturn V Capital Management increased its Immix Biopharma (IMMX) stake by 23% in Q1 2026, buying an estimated $5.1M and bringing the position to 3,693,585 shares worth $33.6M. The position accounts for 6.09% of the portfolio, ranked #6.

Saturn V Capital Management first reported a position in IMMX in Q4 2025 and has held it in 2 quarters since. 77 funds tracked by Wall St. Rank hold IMMX as of Q1 2026.

  • Saturn V Capital Management held 3,693,585 shares of Immix Biopharma worth $33.6M as of Q1 2026.
  • Saturn V Capital Management bought 694,416 Immix Biopharma shares in Q1 2026, an estimated $5.1M.
  • Immix Biopharma made up 6.09% of Saturn V Capital Management's portfolio in Q1 2026, its #6 holding.
  • Saturn V Capital Management first reported a position in Immix Biopharma in Q4 2025 and has held it in 2 quarters since.
  • 77 funds tracked by Wall St. Rank held Immix Biopharma as of Q1 2026.

Based on Saturn V Capital Management's 13F filing for Q1 2026, filed 15 May 2026.